16.12
-1.17(-6.77%)
Currency In USD
Address
645 Summer Street
Boston, MA 02210
United States of America
Phone
617 949 2643
Website
Sector
Healthcare
Industry
Biotechnology
Employees
142
First IPO Date
June 24, 2021
| Name | Title | Pay | Year Born |
| Markus Warmuth | President, Chief Executive Officer & Director | 970,830 | 1971 |
| Sharon Townson | Chief Scientific Officer | 644,600 | 1975 |
| Phil Nickson | Chief Business & Legal Officer | 704,801 | 1979 |
| Filip Janku | Chief Medical Officer | 743,800 | 1974 |
| John C. Castle | Chief Data & Information Officer | 0 | 1971 |
| Andrew Funderburk | Senior Vice President and Head of IR & Strategic Finance | 0 | N/A |
| Edmund Dunn | Senior VP & Corporate Controller | 0 | 1966 |
| Magnus Walter | Senior Vice President of Drug Discovery | 0 | N/A |
| Jennifer Champoux | Chief Operating Officer | 0 | 1972 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.